Current Report Filing (8-k)
15 Mai 2018 - 10:46PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 14, 2018
IMMUNOCELLULAR THERAPEUTICS, LTD.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35560
|
|
93-1301885
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
30721 Russell Ranch Road, Suite
140
Westlake Village, California 91362
(Address of Principal Executive Offices)
(Zip Code)
Registrants telephone number, including area code: (818)
264-2300
|
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 14, 2018, ImmunoCellular Therapeutics, Ltd. (the Company) issued a press release announcing financial results for the
quarter ended March 31, 2018. A copy of this press release is attached as Exhibit 99.1.
This information, including exhibits
attached hereto and the information under item 9.01 below, shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: May 15, 2018
|
|
|
|
IMMUNOCELLULAR THERAPEUTICS, LTD.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ David Fractor
|
|
|
|
|
|
|
David Fractor
|
|
|
|
|
|
|
Principal Accounting Officer
|
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
Von Sep 2023 bis Sep 2024
Echtzeit-Nachrichten über EOM Pharmaceutical Holdings Inc (PK) (OTCMarkets): 0 Nachrichtenartikel
Weitere Immunocellular Therapeutics, Ltd. News-Artikel